The CureCloud study, sponsored by the Multiple Myeloma Research Foundation, seeks to 1) bring the latest cutting-edge discoveries in multiple myeloma research back to the patient in the clinic, and 2) develop robust, real world longitudinal data on a large number of multiple myeloma patients culminating in a registry of about 5,000 multiple myeloma patients. The ultimate goal: bring Precision Medicine to multiple myeloma patients.
Multiple Myeloma, a cancer that forms in a type of white blood cell known as a plasma cell, causes cancer cells to accumulate in the bone marrow, where they crowd out healthy blood cells. Rather than produce helpful antibodies, the cancer cells produce abnormal proteins that trigger complications.
The cause of this disease is unknown but risk factors include obesity, radiation exposure and family history as well as certain chemicals. The American Cancer Society estimates for multiple myeloma in the United States include about 32,270 new cases will be diagnosed (17530 in men and 14,740 in women).
The CureCloud Study
As documented in Clincialtrials.gov there is an urgent need for deeper understanding of the clinical, molecular and immune parameters involved with this disease as well as initiation, progression and response to treatment. With information collected at the population level, the sponsors seek to generate evidence to make Precision Medicine a reality for all multiple myeloma patients.
This is why the multiple Myeloma Research Foundation (MMRF) launched the “CureCloud” Research Initiative, a Direct-to-Patient Research effort aimed at enrolling 5,000 patients from whom comprehensive molecular and immune analyses will be generated from blood specimens. The resulting data will be aggregated with the correlating clinical information.
The study team collects blood from all patients once all electronic online consenting via a mailed blood kit designed for a mobile phlebotomy appointment. Via the study team consulting process, patients will also be authorized to link to their electronic medical records information.
A Key Target
A primary target of the CureCloud study is a curated dataset of integrated genomic, immune and correlating clinical data made available to support scientific investigations via the MMRF. CureCloud is powered by a cloud-based platform with tools and capabilities for seamless aggregation, integration and analysis of large collections of myeloma datasets. The ultimate goal bring Precision Medicine to myeloma patients in the future.
The Observational study commenced July 14, 2020 and will run through till July 31, 2026
Recently, Targeted Oncology presented Jay Cho, MD, PhD, chief medical officer, Multiple Myeloma Research Foundation (MMRF) and associate professor of Mount Sinai Hospital Rutenberg Treatment Center. Dr. Cho discusses the CureCloud study, its goals and objectives and a historical perspective of the MMRF in the quest to ultimately bring the multiple myeloma patient to Precision Medicine.
About the Multiple Myeloma Research Foundation
The Multiple Myeloma Research Foundation (MMRF) drives discoveries for new treatments, accelerates groundbreaking clinical trials and fuels the most robust data-driven initiatives in cancer research. Our goal is to find a cure for each and every patient diagnosed with multiple myeloma.
Call to Action: If you or a loved one has someone close with multiple myeloma, think about participation in this observational study.